Formulation: A solid
Formal Name: N-[3-cyclopropyl-1-[(6-methyl-2-pyridinyl)methyl]-1H-indazol-4-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy]-imidazo[1,2-a]pyridine-3-carboxamide
Purity: ≥98%
Formula Markup: C32H36N8O2
Formula Weight: 564,7
Shelf life (days): 1460
CAS Number: 1313407-95-2
Notes: ARRY-382 is an inhibitor of the colony-stimulating factor 1 receptor (CSF1R; IC50 = 9 nM).{72157} It is selective for CSF1R over PDGFR, c-Kit, and FMS-related tyrosine kinase 3 (FLT3; IC50s = >10,000 nM for all). ARRY-382 (10 µM) induces apoptosis in several primary human chronic lymphocytic leukemia (CLL) cell lines. It also enhances the cytotoxicity of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Item No. 16274) and PI3K p110δ inhibitor idelalisib (CAL-101; Item No. 15279) in several primary human CLL cell lines when used at concentrations ranging from 0.15625 to 10 µM.